000151663 001__ 151663
000151663 005__ 20250604100728.0
000151663 0247_ $$2doi$$a10.1001/jamanetworkopen.2020.6027
000151663 0247_ $$2altmetric$$aaltmetric:82963705
000151663 0247_ $$2pmid$$apmid:32463470
000151663 037__ $$aDZNE-2020-01242
000151663 082__ $$a610
000151663 1001_ $$aMaier, Franziska$$b0
000151663 245__ $$aBupropion for the Treatment of Apathy in Alzheimer Disease
000151663 260__ $$aChicago, Ill.$$bAmerican Medical Association$$c2020
000151663 3367_ $$2DRIVER$$aarticle
000151663 3367_ $$2DataCite$$aOutput Types/Journal article
000151663 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748960293_28492
000151663 3367_ $$2BibTeX$$aARTICLE
000151663 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000151663 3367_ $$00$$2EndNote$$aJournal Article
000151663 520__ $$aImportance  Apathy is a frequent neuropsychiatric symptom in dementia of Alzheimer type and negatively affects the disease course and patients’ and caregivers’ quality of life. Effective treatment options are needed.Objective  To examine the efficacy and safety of the dopamine and noradrenaline reuptake inhibitor bupropion in the treatment of apathy in patients with dementia of Alzheimer type.Design, Setting, and Participants  This 12-week, multicenter, double-blind, placebo-controlled, randomized clinical trial was conducted in a psychiatric and neurological outpatient setting between July 2010 and July 2014 in Germany. Patients with mild-to-moderate dementia of Alzheimer type and clinically relevant apathy were included. Patients with additional clinically relevant depressed mood were excluded. Data analyses were performed between August 2018 and August 2019.Interventions  Patients received either bupropion or placebo (150 mg for 4 weeks plus 300 mg for 8 weeks). In case of intolerability of 300 mg, patients continued to receive 150 mg throughout the study.Main Outcomes and Measures  Change on the Apathy Evaluation Scale–Clinician Version (AES-C) (score range, 18-72 points) between baseline and week 12 was the primary outcome parameter. Secondary outcome parameters included measures of neuropsychiatric symptoms, cognition, activities of daily living, and quality of life. Outcome measures were assessed at baseline and at 4, 8, and 12 weeks.Results  A total of 108 patients (mean [SD] age, 74.8 [5.9] years; 67 men [62%]) were included in the intention-to-treat analysis, with 54 randomized to receive bupropion and 54 randomized to receive placebo. The baseline AES-C score was comparable between the bupropion group and the placebo group (mean [SD], 52.2 [8.7] vs 50.4 [8.2]). After controlling for the baseline AES-C score, site, and comedication with donepezil or galantamine, the mean change in the AES-C score between the bupropion and placebo groups was not statistically significant (mean change, 2.22; 95% CI, –0.47 to 4.91; P = .11). Results on secondary outcomes showed statistically significant differences between bupropion and placebo in terms of total neuropsychiatric symptoms (mean change, 5.52; 95% CI, 2.00 to 9.04; P = .003) and health-related quality of life (uncorrected for multiple comparisons; mean change, –1.66; 95% CI, –3.01 to –0.31; P = .02) with greater improvement in the placebo group. No statistically significant changes between groups were found for activities of daily living (mean change, –2.92; 95% CI, –5.89 to 0.06; P = .05) and cognition (mean change, –0.27; 95% CI, –3.26 to 2.73; P = .86). The numbers of adverse events (bupropion group, 39 patients [72.2%]; placebo group, 33 patients [61.1%]) and serious adverse events (bupropion group, 5 patients [9.3%]; placebo group, 2 patients [3.7%]) were comparable between groups.Conclusions and Relevance  Although it is safe, bupropion was not superior to placebo for the treatment of apathy in patients with dementia of Alzheimer type in the absence of clinically relevant depressed mood.Trial Registration  EU Clinical Trials Register Identifier: 2007-005352-17
000151663 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000151663 588__ $$aDataset connected to CrossRef
000151663 7001_ $$0P:(DE-2719)2811324$$aSpottke, Annika$$b1$$udzne
000151663 7001_ $$aBach, Jan-Philipp$$b2
000151663 7001_ $$0P:(DE-HGF)0$$aBartels, Claudia$$b3
000151663 7001_ $$0P:(DE-2719)2811351$$aBürger, Katharina$$b4$$udzne
000151663 7001_ $$0P:(DE-HGF)0$$aDodel, Richard$$b5
000151663 7001_ $$aFellgiebel, Andreas$$b6
000151663 7001_ $$0P:(DE-2719)2811326$$aFliessbach, Klaus$$b7$$udzne
000151663 7001_ $$0P:(DE-HGF)0$$aFrölich, Lutz$$b8
000151663 7001_ $$aHausner, Lucrezia$$b9
000151663 7001_ $$aHellmich, Martin$$b10
000151663 7001_ $$aKlöppel, Stefan$$b11
000151663 7001_ $$aKlostermann, Arne$$b12
000151663 7001_ $$aKornhuber, Johannes$$b13
000151663 7001_ $$0P:(DE-2719)2000055$$aLaske, Christoph$$b14$$udzne
000151663 7001_ $$0P:(DE-2719)2811024$$aPeters, Oliver$$b15$$udzne
000151663 7001_ $$0P:(DE-2719)2811122$$aPriller, Josef$$b16$$udzne
000151663 7001_ $$aRichter-Schmidinger, Tanja$$b17
000151663 7001_ $$0P:(DE-HGF)0$$aSchneider, Anja$$b18
000151663 7001_ $$aShah-Hosseini, Kija$$b19
000151663 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan$$b20$$udzne
000151663 7001_ $$avon Arnim, Christine A. F.$$b21
000151663 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b22$$udzne
000151663 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b23$$eLast author$$udzne
000151663 773__ $$0PERI:(DE-600)2931249-8$$a10.1001/jamanetworkopen.2020.6027$$gVol. 3, no. 5, p. e206027 -$$n5$$pe206027$$tJAMA network open$$v3$$x2574-3805$$y2020
000151663 8564_ $$uhttps://jamanetwork.com/journals/jamanetworkopen/fullarticle/2766381
000151663 8564_ $$uhttps://pub.dzne.de/record/151663/files/DZNE-2020-01242.pdf$$yOpenAccess
000151663 8564_ $$uhttps://pub.dzne.de/record/151663/files/DZNE-2020-01242.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000151663 909CO $$ooai:pub.dzne.de:151663$$pdnbdelivery$$pdriver$$popenaire$$pVDB$$popen_access
000151663 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811324$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000151663 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811351$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000151663 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811326$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000151663 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000055$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000151663 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811024$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000151663 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811122$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000151663 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b20$$kDZNE
000151663 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b22$$kDZNE
000151663 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b23$$kDZNE
000151663 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000151663 9141_ $$y2020
000151663 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-16
000151663 915__ $$0LIC:(DE-HGF)CCBYNV$$2HGFVOC$$aCreative Commons Attribution CC BY (No Version)
000151663 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJAMA NETW OPEN : 2021$$d2022-11-16
000151663 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-10-18T13:36:16Z
000151663 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-10-18T13:36:16Z
000151663 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJAMA NETW OPEN : 2021$$d2022-11-16
000151663 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-16
000151663 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-16
000151663 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000151663 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-10-18T13:36:16Z
000151663 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-15
000151663 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-16
000151663 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-16
000151663 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-15
000151663 9201_ $$0I:(DE-2719)1011101$$kPatient Studies (Bonn)$$lPatient Studies (Bonn)$$x0
000151663 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x1
000151663 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger$$lTranslational Neurodegeneration$$x2
000151663 9201_ $$0I:(DE-2719)1011103$$kAG Spottke$$lClinical Research Platform (CRP)$$x3
000151663 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x4
000151663 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x5
000151663 9201_ $$0I:(DE-2719)5000000$$kAG Peters$$lBiomarker-Assisted Early Detection of Dementias$$x6
000151663 9201_ $$0I:(DE-2719)5000007$$kAG Priller$$lTranslational Neuropsychiatry$$x7
000151663 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x8
000151663 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x9
000151663 980__ $$ajournal
000151663 980__ $$aVDB
000151663 980__ $$aI:(DE-2719)1011101
000151663 980__ $$aI:(DE-2719)1510100
000151663 980__ $$aI:(DE-2719)1110002
000151663 980__ $$aI:(DE-2719)1011103
000151663 980__ $$aI:(DE-2719)1111015
000151663 980__ $$aI:(DE-2719)1210000
000151663 980__ $$aI:(DE-2719)5000000
000151663 980__ $$aI:(DE-2719)5000007
000151663 980__ $$aI:(DE-2719)1410006
000151663 980__ $$aI:(DE-2719)1011102
000151663 980__ $$aUNRESTRICTED
000151663 9801_ $$aFullTexts